제노레이
Financials
Valuation Metrics
제노레이's Market Cap is ₩488B. At end of 2025 it was ₩605B. Ranked #1787 of 2,421 in KR market (top 74%), #1093 of 1,640 on KOSDAQ (top 67%), #72 of 96 in Health Care Equipment & Services (top 75%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.76B KRW | KR#1,787/2,421 Sec#72/96 |
| Revenue | 107.88B KRW | KR#1,373/2,421 Sec#31/96 |
| Net Income | 2.54B KRW | KR#1,372/2,421 Sec#42/96 |
| Total Assets | 138.33B KRW | KR#1,563/2,421 Sec#47/96 |
| Net Assets | 81.05B KRW | KR#1,578/2,421 Sec#45/96 |
| Employees | 358 | KR#677/2,421 Sec#16/96 |
| Value | ||
| P/E | 19.17x | KR#1,151/2,421 Sec#35/96 |
| P/B | 0.60x | KR#995/2,421 Sec#17/96 |
| P/S | 0.45x | KR#852/2,421 Sec#5/96 |
| FCF Yield | 8.11% | KR#689/2,421 Sec#15/96 |
| Profitability | ||
| ROE | 3.14% | KR#1,318/2,421 Sec#44/96 |
| ROA | 1.84% | KR#1,252/2,421 Sec#47/96 |
| Op. Margin | -1.49% | KR#1,715/2,421 Sec#53/96 |
| Revenue Growth | 2.86% | KR#1,332/2,421 Sec#67/96 |
| Financial Health | ||
| Debt Ratio | 70.68% | KR#1,226/2,421 Sec#68/96 |
| Total Debt | 26.39B KRW | KR#1,284/2,421 Sec#34/96 |
| FCF | 3.96B KRW | KR#960/2,421 Sec#26/96 |
| Cash | 14.20B KRW | KR#1,473/2,421 Sec#44/96 |
| Current Ratio | 1.88x | KR#929/2,421 Sec#56/96 |
| Dividend | ||
| Div. Yield | 4.48% | KR#344/2,421 Sec#2/96 |
| Div. Growth | -16.67% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -36.19% | KR#1,741/2,421 Sec#54/96 |
| 1M Return | 4.52% | KR#792/2,421 Sec#19/96 |
| From 52W High | -40.07% | KR#931/2,421 Sec#26/96 |
| 1Y MDD | -39.51% | KR#566/2,421 Sec#17/96 |
| Trading | ||
| Volume | 3,298 shares | KR#2,208/2,421 Sec#88/96 |
| Trading Value | 10.9M KRW | KR#2,263/2,421 Sec#88/96 |
| Foreign Own. | 1.95% | KR#1,649/2,421 Sec#61/96 |
| Per Share | ||
| EPS | 175 KRW | KR#1,321/2,421 Sec#39/96 |
| BPS | 5,569 KRW | KR#1,410/2,421 Sec#35/96 |
Company Info
Established in 2001 and listed on KOSDAQ in 2018, the company maintains overseas branches in the United States, Germany, Japan, Türkiye, and China. It researches, develops, manufactures, and sells X-ray diagnostic equipment for hospital and dental medical environments, uniquely operating in both medical and dental sectors domestically. Leveraging its proprietary Complementary Metal-Oxide-Semiconductor Flat Panel Detector (CMOS FPD) sensor development and manufacturing technology, the company achieves cost competitiveness and high quality. It internalizes operations from R&D to sales to meet market demands. Genoray is headquartered in Seongnam-si, Gyeonggi-do.